Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.

Name: Kaimen Rigor review — Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
Item: Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
Rating: 59
Author: Alpha1

Wainberg ZA, Manji GA, Bahary N, Ulahannan SV, Pant S, Spigel DR, Uboha NV, Oberstein PE, Saeed A, Beagle B, Kim JY, Wang N, Weeder B, Shitole S, Mrouj K, Scott JR, Ensign LG, DiRenzo DM, Walters MJ, Wu W, Kaplan A, Cho S, Kabbarah O, O'Reilly EM

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3★ (Adequate), 0 critical, 8 high issues for “Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Read alongside

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.

Read full text (PMC)

DOI

10.1038/s41591-026-04283-z

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/499c3dcf-3be9-4b64-af29-a01af34fc1e8" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/499c3dcf-3be9-4b64-af29-a01af34fc1e8/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 8 high issues for “Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

84dc2b1860c9bc2c9055d1fc50bcca6db7b3e572fedafb6993223504e62d659a

Verify via API

Issued Aug 10, 2026Engine 7.29.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.

Paper source

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ReportingKey resources partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: moderateReviewer agreement: moderateEngine: 7.29.0Source: full text

Not verified in this report

References were not verified against Crossref/OpenAlex.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 103AuthenticityData authenticity concerns 204DisclosureReporting gaps 05AvailabilityNone found 06Copyedit8 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The manuscript is a well-designed and transparently reported phase 1b exploratory trial with a strong scientific rationale, sound ethics documentation, and careful, estimation-framed statistical reporting; the 10 machine-recomputed tests were all consistent. Its main weaknesses are in resource authentication (unidentified mIF/ISH antibodies and probes, no cell-line STR authentication or mycoplasma testing) and data/code availability (no sequencing accession numbers, no shared analysis code), plus minor reporting gaps (no CONSORT reference, disclosed-but-unreported secondary endpoints, and a low-severity percentage rounding inconsistency).

Three independent reviewer runs (same model) were synthesized; reviewers converged on six dimensions and diverged on study design (1 warn vs 2 pass) and data code availability (1 fail vs 2 warn), both resolved to the majority with reasoning preserved. Statistics verification recomputed only 10 of the reported tests (those with a statistic + df or effect + CI); threshold-only, q-value, and resampling/exact p-values were not machine-verified and are not endorsed. Citation check was not run (0 references checked). All 5 data/code links verified live; no retracted or not-found references were flagged.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 10 tests: 10 consistent, 0 inconsistent; 7 recomputed directly from the reported test statistics, 3 via agent-written checks.

Overstated conclusions

1 finding · worst low

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

12 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

2 findings · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

Eight Dimensions6 pass · 2 warn

The introduction extensively cites prior research on CD73 and adenosine in cancer, the rationale for targeting CD73 in PDAC, and the limitations of existing adenosine signatures. The hypothesis that CD73 inhibition may benefit patients with mPDAC is logically derived from the cited evidence. The paper acknowledges that previous transcriptional signatures had limited predictive value, and proposes NR4A family expression as a novel surrogate, thereby addressing gaps in prior research.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a strong scientific foundation by citing prior work on CD73, adenosine, and PDAC, providing a logical rationale for the study, and addressing limitations of previous transcriptional signatures.

Evidence

paraphrase[Introduction, paragraph 1]

“The ectonucleotidase CD73 is a key enzyme involved in the production of extracellular adenosine from adenosine triphosphate (ATP).”

“However, these transcriptional signatures have limited predictive value, in part because they may not adequately reflect the cellular heterogeneity in the TME.”

Introduction ¶3Find in source

paraphrase[Introduction, paragraph 3]

“Identification of gene expression profiles reflective of an adenosine-rich immunosuppressed TME... may offer the potential to identify patients with cancer who could benefit from CD73 inhibition.”

PASSReviewer 2· 90% conf

The scientific premise is well established: CD73-mediated adenosine production as an immunosuppressive mechanism in PDAC is thoroughly referenced, and the rationale connecting CD73 inhibition with reversal of immunosuppression is clearly articulated.

Evidence

“However, these transcriptional signatures have limited predictive value, in part because they may not adequately reflect the cellular heterogeneity in the TME.”

IntroductionFind in source

“Quemliclustat is a potent and selective small‑molecule inhibitor of soluble and cell‑bound CD73 that is being studied in multiple tumor types”

IntroductionFind in source

PASSReviewer 3· 90% conf

The manuscript clearly establishes the scientific rationale linking CD73-mediated adenosine generation to immunosuppression in mPDAC and motivates the study from prior work, including acknowledgment of the limitations of existing adenosine transcriptional signatures.

Evidence

“Multiple phase 3 trials of new therapeutic modalities have failed to improve on the standard care for mPDAC”

IntroductionFind in source

“these transcriptional signatures have limited predictive value, in part because they may not adequately reflect the cellular heterogeneity in the TME”

IntroductionFind in source

Randomization used the permuted block method at the patient level. The open-label design is explicitly stated (phase 1b dose-finding context). The sample-size justification is based on an estimation framework with a stated ORR-difference assumption (90% CI 3–37%), appropriate for a descriptive phase 1b study rather than a confirmatory power calculation. Eligibility criteria are given in text and fully in Supplementary Table. The analysis population (safety-evaluable) is defined. For a human phase 1b RCT, replicate_distinction, bench controls, and independent internal replication are not applicable.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 85% conf

The study design is adequately described for a phase 1b trial, including randomization method and inclusion/exclusion criteria, but lacks a formal power analysis and detailed blinding justification.

Evidence

“patients were enrolled and randomized 2:1 using the permuted block method”

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting